A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects

NCT07327281

Status	RECRUITING
Phase	Phase 1
Sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Enrollment	66 participants

Key Eligibility Criteria

Inclusion (4)

- Chinese subjects aged above 18 years old (including 18 years old) and below 55 years old (including 55 years old);
- Those who voluntarily sign a written informed consent form before the trial, have a full understanding of the trial content, process and possible adverse reactions, can communicate well with the researcher, and understand and comply with the requirements of this study;
- Women of childbearing potential should agree to use effective contraceptive measures during the study and for 6 months after the end of the study;
- Male weight e50 kg, female weight e45 kg, body mass index (BMI) between 20-40kg/m2 (including both ends of the cutoff);

Exclusion (25)

- Pregnant and lactating women.
- Those whose vital signs, physical examination, laboratory examination, 12-lead electrocardiogram, anteroposterior chest X-ray, and abdominal ultrasound results during the screening period are abnormal and have clinical significance.
- Those who have had or currently have diseases/abnormalities such as heart, endocrine, metabolism, kidney, liver, gastrointestinal tract, skin, infection, blood, nerve or mental illness, or related chronic diseases, or acute diseases, and the researcher assesses that they are not suitable to participate in the trial:
- Have active tuberculosis during the screening period, or be a close household contact of an untreated active tuberculosis patient.
- Have a history of severe bacterial, fungal or viral infection within 2 months before randomization, requiring hospitalization with intravenous antibiotics or antiviral drug treatment;

... and 20 more (see full listing online)

Locations (1 total)

Drum Tower Hospital Affiliated to Nanjing University School of Medicine, Nanjing, Jiangsu, China